The reiteration of a Buy rating and maintenance of a $13 price target by Needham analyst Serge Belanger indicates a positive outlook for Cormedix's stock. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's potential.